JP2022121359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022121359A5 JP2022121359A5 JP2021131089A JP2021131089A JP2022121359A5 JP 2022121359 A5 JP2022121359 A5 JP 2022121359A5 JP 2021131089 A JP2021131089 A JP 2021131089A JP 2021131089 A JP2021131089 A JP 2021131089A JP 2022121359 A5 JP2022121359 A5 JP 2022121359A5
- Authority
- JP
- Japan
- Prior art keywords
- thr
- pharmaceutical composition
- ser
- asn
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000225 synapse Anatomy 0.000 claims description 17
- 210000003520 dendritic spine Anatomy 0.000 claims description 16
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims description 9
- 239000002559 chemokine receptor antagonist Substances 0.000 claims description 9
- 208000014644 Brain disease Diseases 0.000 claims description 8
- 208000032274 Encephalopathy Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000001149 cognitive effect Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000016192 Demyelinating disease Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000032859 Synucleinopathies Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 3
- 210000000020 growth cone Anatomy 0.000 claims description 3
- 230000007514 neuronal growth Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- KVPFYRAFNZKJSD-CPXLMRBJSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 KVPFYRAFNZKJSD-CPXLMRBJSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- JXMREEPBRANWBY-VEVYYDQMSA-N Asn-Thr-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JXMREEPBRANWBY-VEVYYDQMSA-N 0.000 claims description 2
- QVXWAFZDWRLXTI-NWLDYVSISA-N Glu-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O QVXWAFZDWRLXTI-NWLDYVSISA-N 0.000 claims description 2
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 claims description 2
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 claims description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 206010060860 Neurological symptom Diseases 0.000 claims description 2
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 230000006399 behavior Effects 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 108010053037 kyotorphin Proteins 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 230000000699 topical effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 6
- 150000008574 D-amino acids Chemical group 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 2
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102100023684 Kelch-like protein 17 Human genes 0.000 description 1
- 101710173261 Kelch-like protein 17 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062970869P | 2020-02-06 | 2020-02-06 | |
| US17/170,790 US20210244788A1 (en) | 2020-02-06 | 2021-02-08 | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines |
| US17/170,790 | 2021-02-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022121359A JP2022121359A (ja) | 2022-08-19 |
| JP2022121359A5 true JP2022121359A5 (https=) | 2024-09-04 |
Family
ID=77178645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131089A Pending JP2022121359A (ja) | 2020-02-06 | 2021-08-11 | シナプスおよび樹状突起棘の喪失を逆転させるための複数のケモカインレセプターの経口用ペプチドアンタゴニスト |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20210244788A1 (https=) |
| JP (1) | JP2022121359A (https=) |
| CN (1) | CN114903990A (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116990520A (zh) * | 2022-04-25 | 2023-11-03 | 中国科学院深圳先进技术研究院 | 一种蛋白棒状体标志物及其应用 |
| WO2025124536A1 (zh) * | 2023-12-15 | 2025-06-19 | 江苏康缘药业股份有限公司 | 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567682A (en) * | 1988-12-16 | 1996-10-22 | Advanced Peptides And Biotechnology Sciences | Method of treating Alzheimer's disease |
| AU2006261133B2 (en) * | 2005-06-23 | 2012-04-05 | Rapid Pharmaceuticals Ag | Therapeutic peptides and vaccines |
| US20140322251A1 (en) * | 2013-04-26 | 2014-10-30 | Michael Ruff | Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions |
| US20190022166A1 (en) * | 2017-07-18 | 2019-01-24 | Creative Bio-Peptides Inc. | Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders |
| WO2019135995A1 (en) * | 2018-01-02 | 2019-07-11 | Rush University Medical Center | Compositions and methods for treating neurological disorders |
-
2021
- 2021-02-08 US US17/170,790 patent/US20210244788A1/en not_active Abandoned
- 2021-08-11 JP JP2021131089A patent/JP2022121359A/ja active Pending
- 2021-08-11 CN CN202110921599.2A patent/CN114903990A/zh active Pending
-
2023
- 2023-11-17 US US18/512,201 patent/US20240238363A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121359A5 (https=) | ||
| DE69433301T2 (de) | Methoden zur erhöhung der biologischen aktivität von chemokinen | |
| EP0994850B1 (en) | Inhibition of hiv-1 replication using oligocarbamate derivatives | |
| US20140322252A1 (en) | Peptides for Treating Alzheimers's Disease and Related Conditions | |
| JP2003503312A5 (https=) | ||
| RU98118091A (ru) | Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина | |
| US5679715A (en) | Method for treating multiple sclerosis | |
| KR100995814B1 (ko) | 신규한 오메가―코노톡신 | |
| KR101661332B1 (ko) | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 | |
| EP0456758A1 (en) | Anaphylatoxin-receptor ligands | |
| JPH06116284A (ja) | 新規ペプチド | |
| US6468969B1 (en) | Inhibition of HIV-1 replication using d-amino acid peptides | |
| IE902547A1 (en) | Hemoregulatory peptides | |
| JP2021091728A5 (https=) | ||
| JPH07267988A (ja) | 新規ペプチド | |
| DE60035192T2 (de) | Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung | |
| US6426330B1 (en) | Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it | |
| US5534495A (en) | Treatment of non-HIV neuropathic pain syndromes | |
| CN114903990A (zh) | 用于逆转突触和树突棘损失的多种趋化因子受体的口服肽拮抗剂 | |
| JP2002539829A5 (https=) | ||
| EP1940436B1 (en) | Methods for treating immune mediated neurological diseases | |
| JPH0769919A (ja) | Ｖｉｐ，その類縁体またはそのフラグメントを含む医薬組成物 | |
| CA2465667A1 (en) | New peptides - analogs of human growth hormone-releasing hormone | |
| CN1282657C (zh) | 蝎抗神经兴奋肽 | |
| CN108084247B (zh) | 一种合成多肽及其合成方法和应用 |